No Data
Zhejiang Jingxin Pharmaceutical (002020.SZ): The Phase II clinical trial of Kangfu Xinchangrong Capsules is currently in its final stages.
On December 3, Gelonghui reported that Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the Phase II clinical trial of the Rehabilitation New Enteric Capsule is nearing its conclusion, and the company will promptly advance the Phase III clinical trial of this product according to plan after completing Phase II.
Zhejiang Jingxin Pharmaceutical's Insomnia Drug Added to National Medical Insurance Catalog
Express News | Over 20 listed companies announced after hours that pharmaceuticals have been included in the new national medical insurance catalog, with multiple innovative drugs among them.
Express News | Zhejiang Jingxin Pharmaceutical: Cidofovir capsules included in the national medical insurance catalog.
zhejiang jingxin pharmaceutical (002020.SZ): The national negotiations on Detasini capsules have been completed
On November 27, Gelonghui reported that zhejiang jingxin pharmaceutical (002020.SZ) stated on the investor interaction platform that the negotiations for the Didasine capsules have been completed. The company will announce according to the requirements of the information disclosure rules once the negotiation results are published.
Zhejiang Jingxin Pharmaceutical (002020): Q3 performance meets expectations, continuous manifestation of marketing reform results.
Event: The company released the third quarter report of 2024. In the first three quarters of 2024, the company achieved revenue of 3.209 billion yuan (+9.68% YoY) and net income attributable to the parent of 0.575 billion yuan (+21.66% YoY), after deduction.
No Data
No Data